Identification and Characterization of Cefazolin-Induced Liver Injury.

PubWeight™: 0.79‹?›

🔗 View Article (PMID 25528012)

Published in Clin Gastroenterol Hepatol on December 18, 2014

Authors

Saleh A Alqahtani1, David E Kleiner2, Marwan Ghabril3, Jiezhun Gu4, Jay H Hoofnagle5, Don C Rockey6, Drug-Induced Liver Injury Network (DILIN) Study Investigators

Author Affiliations

1: Division of Digestive and Liver Diseases, The University of Texas Southwestern, Dallas, Texas.
2: Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
3: Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
4: Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
5: Liver Disease Research Branch, Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
6: Division of Digestive and Liver Diseases, The University of Texas Southwestern, Dallas, Texas. Electronic address: rockey@musc.edu.

Articles cited by this

The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med (1992) 6.05

Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45

Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology (2005) 3.52

Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf (2009) 3.48

Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology (2013) 2.72

Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30

The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. Clin Infect Dis (2006) 2.27

Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl (2004) 1.96

Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking. Clin Exp Dermatol (2011) 1.76

Cephalexin-induced cholestatic hepatitis. J Clin Gastroenterol (2004) 1.66

A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med (1990) 1.63

Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment Pharmacol Ther (2006) 1.43

Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg (1992) 1.34

Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology (2006) 1.32

Third-generation cephalosporins. Med Clin North Am (1995) 1.11

Suspected drug-induced liver fatalities reported to the WHO database. Dig Liver Dis (2005) 1.09

Cefdinir-induced hepatotoxicity: potential hazards of inappropriate antibiotic use. J Gen Intern Med (2008) 1.06

Augmentation mammaplasty: postoperative cephalosporin-induced hepatitis. Plast Reconstr Surg (2007) 1.02

Cephalexin nephrotoxicity. Reversible nonoliguric acute renal failure and hepatotoxicity associated with cephalexin therapy. JAMA (1974) 0.94

Jaundice associated with cephalosporin therapy. Drug Intell Clin Pharm (1985) 0.92

Ceftriaxone-induced toxic hepatitis. World J Gastroenterol (2009) 0.91

Acute hepatitis, autoimmune hemolytic anemia, and erythroblastocytopenia induced by ceftriaxone. Am J Gastroenterol (1998) 0.86

Cephalosporin-induced cholestatic jaundice. Lancet (1982) 0.84

A rare case of hepatitis associated with cefprozil therapy. Scand J Infect Dis (2007) 0.83

Third generation cephalosporins. Infect Dis Clin North Am (1989) 0.82

Cholestatic hepatitis with intravenous ceftriaxone. Indian J Pharmacol (2011) 0.81

A fatal case of fulminant hepatic necrosis following sevoflurane anesthesia. Toxicol Pathol (2007) 0.80

Cephalosporins: rationale for clinical use. Am Fam Physician (1991) 0.80

First case of ivermectin-induced severe hepatitis. Trans R Soc Trop Med Hyg (2006) 0.79

Cefixime-induced hepatotoxicity. Turk J Gastroenterol (2011) 0.78

The selection and use of cephalosporins: a review. Adv Ther (1995) 0.77